Baby born in US from an over‑30‑year‑old embryo breaks record
The embryo of Thaddeus Daniel Pierce, who was born on July 26, had been cryopreserved since 1994, according to MIT Technology Review, which broke the story.
His parents, Lindsey and Tim Pierce, who live in the US state of Ohio, "adopted" the embryo from the 62-year-old woman who created it.
The couple said those in their lives had likened it to "something from a sci-fi movie".
Mr Pierce was a toddler when his son's embryo was first created, and Thaddeus also has a 30-year-old sister.
The previous record-holder for an embryo that was frozen before a successful live birth was a pair of twins who were born in 2022 from embryos frozen in 1992.
Linda Archerd, who donated the embryo, said it had been "pretty surreal".
"It's hard to even believe," she told the US journal.
The birth was made possible with the assistance of a Christian embryo adoption service.
These services believe an embryo is equivalent to a born child and look to reduce the number of discarded embryos.
This includes the case of frozen embryos that have been stored in outdated ways.
Ms Archerd originally froze four embryos with the Snowflakes Embryo Adoption Program run by the Nightlight Christian Adoptions agency.
After having her own daughter, the other three were left in storage, and despite divorcing her husband, she did not want to discard the embryos.
The program Ms Archerd used also allows donors to choose a couple, and can state religious, racial and nationality preferences.
She wanted a white, married Christian couple from the US.
"I didn't want them to go out of the country," Mr Archerd told the journal.
"And being Christian is very important to me, because I am."
Ms Archerd finally found her match in the Pierces, who had been trying to have a child for seven years.
"We didn't go into it thinking we would break any records," Mrs Pierce told the journal.
"We just wanted to have a baby."
The pair say, despite a rough birth, both Mrs Pierce and Thaddeus are doing well.
Ms Archerd said he looks just like her own daughter as a baby.
"I pulled out my baby book and compared them side by side, and there is no doubt that they are siblings."
Snowflakes' vice-president Elizabeth Button said the embryo adoption program honours Ms Archerd for donating her remaining embryos, and Mr and Mrs Pierce for adopting embryos that many fertility clinics would not have taken a chance on.
"Though we encourage placing families to make decisions sooner rather than later regarding their remaining embryos, this story affirms that frozen embryos do not have a 'shelf life'. All are deserving of the opportunity to be born."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
19 hours ago
- Perth Now
NASA planning nuclear reactor on the moon: reports
The idea of a nuclear reactor on the moon is not new as Russia proposed the concept years ago. (AP PHOTO) The idea of a nuclear reactor on the moon is not new as Russia proposed the concept years ago. (AP PHOTO) Credit: AAP US space agency NASA is planning to build a nuclear reactor on the surface of the moon, news outlet Politico reports, citing internal agency documents. The space agency reportedly intends to solicit concrete proposals from industry within 60 days for a 100-kilowatt reactor set to go into operation by 2030. Acting NASA administrator Sean Duffy is expected to announce the plans in the coming days, according to Monday's report. The plan comes against the backdrop of intensifying competition with China, which is aiming to launch its first crewed moon mission around the same time. The NASA document warns the first nation to deploy a working reactor could "declare a keep-out zone which would significantly inhibit the United States," according to Politico. The idea of a nuclear reactor on the moon is not new. Russia proposed the concept years ago and NASA has recently stepped up its own research. A reactor would provide the stable power supply needed for future moon missions, especially during the roughly two-week-long lunar night when solar energy is unavailable. The US is aiming to return astronauts to the moon for the first time in more than 50 years. Under its Artemis program, NASA plans to land a crew on the lunar surface in 2027. However, the timeline has already been pushed back multiple times and it remains unclear whether President Donald Trump will continue to support the effort.
The Australian
20 hours ago
- The Australian
Compumedics wins sales as broker lifts target ~140pc
Compumedics secures two lucrative sales for its Somfit sleep device with combined revenues approaching $2 million Sales to a leading CRO in US and a Finnish pharmaceutical company support strategy to expand in adjacent markets East Coast Research revises Compumedics target price to 75 cents per share, showing upside potential of 138.7% Special Report: Compumedics has secured lucrative multiple Somfit sales to leading pharmaceutical and clinical research organisations (CROs) in the US and Europe East Coast Research sees an almost 140% upside to its current target price. Compumedics (ASX: CMP), a global medical device company specialising in sleep, brain and ultrasonic blood flow monitoring, has inked a sale with a leading CRO for its Somfit devices. The company noted the devices will be used in a major US-based clinical drug trial with one of the world's largest pharmaceutical companies. Compumedics also secured a second sale with Finland-based global pharmaceutical firm Orion Pharma for deployment of Somfit devices across a multi-country, multi-centre clinical study in Europe. Somfit is a wearable device used for collecting physiological data during sleep with combined revenues from both sales approaching $2 million. The sales support the company's strategy to expand into adjacent markets, where Somfit's ability to collect electroencephalography (EEG) signals and provide insights into sleep stages and patterns provides a distinct advantage over traditional home sleep testing systems. The contracts also validate Somfit's clinical value proposition in the pharmaceutical sector, where understanding the effects of new drugs on sleep is becoming an increasingly important regulatory and research requirement. 'Building a diversified global business' Executive chairman and CEO Dr David Burton said the sales wins highlight the growing momentum Compumedics was seeing for Somfit in new market segments. 'The pharmaceutical clinical trial market is an ideal adjacency for our technology, and these early contracts, approaching $2 million in combined value, demonstrate Somfit's versatility beyond traditional home sleep testing,' 'This is another important step in building a diversified global business with multiple high growth pathways." Compumedics expects to build on this early traction, continuing engagement with major pharmaceutical companies and research institutions worldwide. Broker re-rates Compumedics following milestones and global expansion Meanwhile, East Coast Research has revised its target price for Compumedics to 75 cents per share, representing an upside potential of 138.7% from the share price at the time of its review and an 11.9% increase on its previous 67 cent target set in March. In its updated valuation, East Coast Research set a base case of 59 cents per share and an upside case of 92 cents, with a price-to-NAV (net asset value) of 0.42x. The Sydney-based equity research house said the re-rating reflected several key achievements, including: Record FY25 sales orders of $63.4m, up 22% YoY and return to profitability with $3m EBITDA for the financial year Validation of its world-first dual-use Orion LifeSpan MEG system Strong FY26 guidance with $70m in revenue and $9m in EBITDA supported by US launch of Somfit D, rising SaaS contributions and delivery of three MEG systems A $24.4 million pipeline secured through two long-term distribution agreements in China Broader entry into pharmaceutical trials 'These developments not only strengthen CMP's position in high-growth segments like SaaS and brain imaging but also significantly de-risk its revenue outlook and enhance its value proposition in the global medtech and connected health markets,' the broker noted. East Coast said Compumedics remained well-positioned for long-term value creation. This article was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
The Australian
a day ago
- The Australian
Imagion raises $3.5m to advance early cancer detection clinical program
Imagion secures $3.5 million in capital raise to sophisticated investors and family offices Placement to support ongoing clinical program for MagSense Imaging agent for cancer Company currently preparing to undertake Phase II trial in HER2+ breast cancer in the US Special Report: Imagion Biosystems has raised $3.5 million through a heavily oversubscribed two-tranche placement to sophisticated investors and family offices as it prepares to launch a Phase II trial of its MagSense imaging technology for HER2+ breast cancer in the US. The placement, led by CPS Capital, was priced at 1.5 cents per share with one free attaching listed option exercisable at 4 cents and expiring on December 13, 2027. The offer price represented a 10% discount to the 10-day volume-weighted average price (VWAP) for Imagion Biosystems (ASX:IBX) shares before announcement of the capital raising. Directors will also contribute $150,000 based on the same terms and conditions, subject to shareholder approval at an extraordinary general meeting in September. The placement consists of two tranches including: Tranche 1 –45 million new shares to raise ~$675,000 with settlement on August 5 and allotment of new shares on August 6 Tranche 2 – The balance of shares (~$2.8m) conditional on shareholder approval at an EGM The EGM is scheduled for September 18 with settlement of tranche 2 earmarked for September 19. Allotment of new shares under tranche 2 and new listed options under both tranches is set for September 22. Listen to more from IBX: Imagion's cancer imaging alternative Use of proceeds to advance clinical program Funds will be used to advance Imagion's MagSense imaging technology, specifically for HER2 breast cancer and initiate the Phase I clinical programs for both prostate and ovarian cancer. Imagion's trademarked platform aims to revolutionise cancer diagnosis by introducing molecular imaging to MRI. The company expects to initiate its HER2 breast cancer trial in the near term with key objectives for the company including: Submission of an investigational new drug (IND) application to the US Food and Drug Administration (FDA) Completion of drug manufacturing to support the trial Filing of new intellectual property (IP) applications related to molecular MRI Initiation of the trial and completion of first patient cohort Collaborations with MRI experts to develop a quantitative MRI platform and AI-based modelling optimised for MagSense 'We are very pleased with the strong demand we saw from investors following our recently announced progress with the FDA on the IND submission for our upcoming HER2+ Breast Cancer Phase 2 clinical trial,' IBX executive chairman Robert Proulx said. 'I want to thank CPS Capital for their lead role and all the investors who have shown their support for our clinical plan.' This article was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Sponsored Nova Minerals has released a conceptual processing flowsheet for its 1.24Moz RPM deposit in Alaska. Sponsored Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease.
